Hypnotics

Advisory - Health Canada warns Canadians about U-Dream herbal sleep-aid products after tests detect a substance similar to a prescription insomnia drug, which may pose serious health risks

Retrieved on: 
Monday, December 23, 2019
RTT, Hallucination, Hypnotics, Sedatives, GABAA receptor positive allosteric modulators

Side effects include drowsiness, dizziness, memory loss, hallucinations and abnormal sleep behaviours while not fully awake including sleep driving (which can result in serious injuries).

Key Points: 
  • Side effects include drowsiness, dizziness, memory loss, hallucinations and abnormal sleep behaviours while not fully awake including sleep driving (which can result in serious injuries).
  • Health Canada tested the products after receiving complaints of unusual side effectssuch as symptoms of withdrawal and dependencesuggesting that the products may contain a substance not listed on the product label.
  • Health Canada has asked Biotrade Canada Ltd. to recall the products and will take further action as needed.
  • Health Canada has suspended the following product licences held by Biotrade Canada Ltd.:

U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients

Retrieved on: 
Monday, December 23, 2019
Psychoactive drugs, Chemical compounds, Hypnotics, Branches of biology, Organofluorides, G protein-coupled receptors, Cyclopropanes, Lemborexant, Pyrimidines, Orexin antagonist, Orexin receptor, Orexin

Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.

Key Points: 
  • Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.
  • Patients were randomized to placebo (n=208), DAYVIGO 5 mg (n=266) or 10 mg (n=269), or active comparator (n=263) once nightly.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Patients with Compromised Respiratory Function:
    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function.

World Insomnia Treatment Market Outlook Report, 2019-2024 - Orexin Antagonist Expected to Grow Rapidly During the Forecast Period Due to Its Greater Efficacy Than Other Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 28, 2019
Pharmaceutical, Health, Mental health, Psychoactive drugs, Chemical compounds, GABAA receptor positive allosteric modulators, Branches of biology, Hypnotics, RTT, Sedatives, Pyrazolopyrimidines, Orexin, Insomnia, Nonbenzodiazepine, Benzodiazepine

The study suggests that insomnia has become one of the most prevalent disorders being reported in the primary care setup.

Key Points: 
  • The study suggests that insomnia has become one of the most prevalent disorders being reported in the primary care setup.
  • Moreover, the growth of psychological conditions and constantly increasing noise levels in the urban areas will also propel the insomnia treatment market, during the forecast period.
  • The global insomnia treatment market is segmented based on treatment type, which includes benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonist, melatonin antagonist, and other treatment types.
  • The orexin antagonist segment is expected to grow rapidly during the forecast period due to its greater efficacy than other drugs.

2019 Tert-butanol Market Study - Global Industry Analysis, Size, Share, Growth, Trends & Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 18, 2019
Chemicals, Plastics, Manufacturing, Alcohols, Chemistry, GABAA receptor positive allosteric modulators, Hypnotics, Sedatives, Butanol, tert-Butyl alcohol, Market research

The "Tert-butanol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tert-butanol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The tert-butanol market report encompasses an incisive analysis of the market drivers, restraints, growth opportunities, and challenges in the market.
  • The report presents an exhaustive research on the current market trends, and how the tert-butanol market has shaped up during the forecast period of 2019-2027.
  • The tert-butanol market study sheds light on the key shifts in consumer behavior and their impact on the business strategies adopted by key market players.

New Jersey's Leading Drug and Alcohol Detox Program To Open A Freehold, New Jersey Location

Retrieved on: 
Wednesday, October 16, 2019
Psychoactive drugs, Substance dependence, Benzodiazepine, Hypnotics, Sedatives, Detoxification, Stimulant

CNT is New Jersey's first licensed ambulatory (outpatient) detoxification program for all substances of abuse, including alcohol, anesthetics, benzodiazepines, opiates, stimulants and others.

Key Points: 
  • CNT is New Jersey's first licensed ambulatory (outpatient) detoxification program for all substances of abuse, including alcohol, anesthetics, benzodiazepines, opiates, stimulants and others.
  • Outpatient treatment delivers better outcomes by incorporating the living environment into treatment and engaging the patient's family in treatment.
  • If you or a loved one have a problem with drugs or alcohol now is the time to seek treatment.
  • Led by Board Certified Addiction Psychiatrist, Indra Cidambi, M.D., experienced physicians and nurses provide high-quality treatment.

Three New Analyses of Data Expand Understanding of the Potential Role for Investigational Agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder

Retrieved on: 
Friday, September 27, 2019
Chemical compounds, Chemistry, Branches of biology, Hypnotics, Organofluorides, Pyrimidines, Pyridines, Cyclopropanes, Lemborexant, Magnesium in biology, MG Cars

Active-only treatment period data for patients who received lemborexant in the first six months was presented at 2019 World Sleep Congress.

Key Points: 
  • Active-only treatment period data for patients who received lemborexant in the first six months was presented at 2019 World Sleep Congress.
  • Lemborexant 10 mg resulted in mean increases in sSE from baseline of 15.6% at six months and 17.6% at 12 months.
  • Lemborexant 10 mg resulted in mean reductions from baseline of 48.1 minutes at six months and 56.8 minutes at 12 months.
  • A small proportion of patients discontinued the study due to a TEAE (lemborexant 5 mg, 1.6%; lemborexant 10 mg, 1.8%).

Eisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World Sleep Congress

Retrieved on: 
Thursday, September 19, 2019
Chemical compounds, Psychoactive drugs, RTT, Psychiatric diagnosis, Psychiatry, Cognitive disorders, Learning disabilities, Hypnotics, Lemborexant, Insomnia, Dementia, Alzheimer's disease

Earlier this year, the U.S. Food and Drug Administration accepted for review the New Drug Application for lemborexant for the treatment of insomnia.

Key Points: 
  • Earlier this year, the U.S. Food and Drug Administration accepted for review the New Drug Application for lemborexant for the treatment of insomnia.
  • This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety.
  • There is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval.
  • Additionally, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia is underway.

Tert-butanol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Retrieved on: 
Wednesday, July 17, 2019
Alcohols, Chemistry, GABAA receptor positive allosteric modulators, Hypnotics, Sedatives, Fatty alcohols, Butanol, tert-Butyl alcohol

The analyst recently published a market report on the tert-butanol market.The tert-butanol market report encompasses an incisive analysis of the market drivers, restraints, growth opportunities, and challenges in the market.

Key Points: 
  • The analyst recently published a market report on the tert-butanol market.The tert-butanol market report encompasses an incisive analysis of the market drivers, restraints, growth opportunities, and challenges in the market.
  • The report covers the notable developments and trade dynamics in order to ascertain the growth prospects of the tert-butanol market.
  • This study offers key market figures and forecast analysis based on exhaustive research on the market structure and the historical trends in the tert-butanol market.
  • The information provided in the study on the tert-butanol market helps readers gain a better understanding of the behavior of the tert-butanol market.

S & B Selected by LyondellBasell to Perform Construction for Ethers Unit for World-Scale PO/TBA Project in US Gulf Coast

Retrieved on: 
Wednesday, June 26, 2019
Manufacturing, Commercial Building & Real Estate, Construction & Property, Chemicals, Plastics, Chemistry, Physical sciences, Organic chemistry, Functional groups, Commodity chemicals, Hypnotics, Sedatives, tert-Butyl alcohol, Propylene oxide, LyondellBasell, Ether, Basell Polyolefins

View the full release here: https://www.businesswire.com/news/home/20190626005045/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190626005045/en/
    S & B will perform construction for a portion of LyondellBasell's PO/TBA Project, which will install the world's largest propylene oxide and tertiary butyl alcohol plant.
  • (Photo: Business Wire)
    Under the contract, S & B is constructing the new 34-acre ethers unit at LyondellBasells Bayport Complex in Pasadena.
  • S & B is honored to be trusted by the client with such an important and historic project, said Tommy Collins, Executive Vice President and COO of S & B.
  • About S & B Engineers and Constructors, Ltd.
    S & B was founded over 50 years ago on the principles of honesty, integrity and safety.

Quidel Receives 510(k) Clearance for Quidel Triage® TOX Drug Screen, 94600 Toxicology Test for Use With Quidel’s Triage® MeterPro Instrumented System

Retrieved on: 
Wednesday, June 19, 2019
Software, Pharmaceutical, Hardware, Data management, Mental health, Technology, Medical devices, FDA, Health, Psychoactive drugs, Neurochemistry, GABAA receptor positive allosteric modulators, Hypnotics, Receptor antagonists, Drug test, Tests, Workplace, Benzodiazepine, Barbiturate, Depressant

The test is to be used with Quidels Triage MeterPro instrumented system.

Key Points: 
  • The test is to be used with Quidels Triage MeterPro instrumented system.
  • Benzodiazepines, tricyclic antidepressants, barbiturates and opiate compounds are among a group of prescription drugs that also are frequently abused.
  • The Quidel Triage TOX Drug Screen, 94600 uses distinct immunoassays for the simultaneous detection of drug and/or the urinary metabolites of up to 9 different drug classes.
  • The positive or negative results are typically displayed on the Quidel Triage MeterPro screen in approximately 15 minutes from the addition of specimen.